RESEARCH Open Access

Effects of menopausal hormone therapy on ambulatory blood pressure and arterial stiffness in postmenopausal Korean women with grade 1 hypertension: a randomized, placebo-controlled trial

Byung-Koo Yoon 1*, Jidong Sung 2*, Yun-Mi Song 3*, Soo-Min Kim 1*, Kyung-A Son 1*, Jun Hyun Yoo 3*, Sung-Ji Park 2* and Duk-Kyung Kim 2*

Abstract

Background: Estrogen therapy in early menopausal women decreases the risk of coronary heart disease and parenteral, but not oral, estrogen is reported to reduce blood pressure (BP). Progestogens are typically added to estrogens to prevent unopposed endometrial stimulation. The effects of progestogen on BP have been less well studied to date. This study was conducted to explore the impacts of micronized progesterone (MP4) combined with percutaneous estradiol gel (PEG) on hemodynamics in postmenopausal Korean women with grade 1 hypertension.

Methods: Fifty-two postmenopausal women (aged 49–75 years) with systolic BP (SBP) of 140–160 mmHg or diastolic BP (DBP) of 90–100 mmHg were randomly assigned for 12 weeks to placebo (n = 16), estrogen therapy (ET) (n = 19) with PEG (0.1 %, 1 g./d), or estrogen + progestogen therapy (EPT, n = 17) with PEG and MP4 (100 mg/d). The primary endpoint was ambulatory BP and the secondary endpoints were arterial stiffness as brachial-ankle pulse-wave velocity (baPWV) and aortic parameters on applanation tonometry.

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Conclusions: There was no difference in ambulatory BP between ET and EPT in postmenopausal Korean women with grade 1 hypertension. Further, ET and EPT similarly decreased baPWV from baseline as compared with placebo. MP4 might not adversely influence estrogen effects on ambulatory BP and arterial stiffness.

Trial registration: Clinical Research Information Registry, KCT0005405, Registered 22 September 2020 - Retrospectively registered, https://cris.nih.go.kr/cris/search/detailSearch.do?all_type=Y&search_page=L&pageSize=10&page=1&seq=17608&search_lang=E.

Keywords: Hormone replacement therapy, Estradiol, Progestins, Hypertension, Vascular stiffness

Results: One woman in the ET group dropped out, so 51 participants were finally analyzed. Outcome measures for ambulatory BP and arterial stiffness were not different between groups. Within-group comparisons showed that EPT significantly decreased daytime heart rate and baPWV: the changes from baseline (mean ± standard deviation) were −2.5 ± 5.7 bpm ($P = 0.03$) and −0.6 ± 1.4 m/s ($P = 0.04$), respectively. After adjusting for baseline, linear regression analysis revealed a significant difference in the relationship between baseline and 12-week baPWV among groups ($P = 0.02$). The relationship was significantly different between placebo and ET ($P = 0.03$) and EPT ($P = 0.01$), respectively, but not between ET and EPT. Additionally, pooled results of active treatments disclosed that SBP, DBP, PWV, and augmentation index at the aorta were significantly reduced relative to baseline.

Conclusions: There was no difference in ambulatory BP between ET and EPT in postmenopausal Korean women with grade 1 hypertension. Further, ET and EPT similarly decreased baPWV from baseline as compared with placebo. MP4 might not adversely influence estrogen effects on ambulatory BP and arterial stiffness.

Background
Cardiovascular disease (CVD) including coronary heart disease (CHD) and stroke is the number 1 cause of death among women worldwide [1] and hypertension belongs to the group of major risk factors of CVD with the strongest evidence for causation [2]. Based on office blood pressure (BP), hypertension is defined as a systolic BP (SBP) of 140 mmHg or higher and/or diastolic BP (DBP) of 90 mmHg or higher. In the case of grade 1 hypertension with a low risk of CVD, lifestyle modifications including dietary alterations may be sufficient to delay or prevent the need for pharmacological intervention [3].

Ambulatory BP monitoring (ABPM) can identify white-coat and masked hypertension, provides night-time readings, and is a stronger predictor of all-cause and cardiovascular mortality when compared with clinic BP [4]. The loss of arterial elasticity leads to an increase in SBP and a decrease in DBP [3]. Thus, arterial stiffness can precede hypertension and, importantly, be reversible in conjunction with lifestyle change or anti-hypertensive treatment [5].

A sex difference in the prevalence of hypertension is apparent: such is lower in women aged 20 to 34 years than in men but increases steeply after menopause, leading to a cross-over after the age of 70 years [6, 7]. Further, the role of hypertension in death is greater in women than in men [8]. These statistics strongly suggest a key role of endogenous ovarian hormones in hypertension. If initiated in early menopause, menopausal hormone therapy (MHT) using oral estrogen decreases the risk for CHD but has no impact on stroke [9]. This might be attributable to a higher contribution of hypertension to development of stroke than CHD [2]. The effects of estrogen therapy on BP may differ by the route of administration probably via a first-pass hepatic effect.

Conjugated equine estrogen (CEE), an oral estrogen, increases the clinic BP [10], whereas parenteral estrogen using a transdermal patch decreases ambulatory BP in postmenopausal women with both hypertension [11] and normal BP [12]. When compared with patch application, percutaneous estradiol gel (PEG), another parenteral preparation, has lower adverse skin effects and could provide higher estradiol serum values with less day-to-day variation [13]. Progestogens are typically added to estrogens to prevent unopposed endometrial stimulation. Medroxyprogesterone acetate (MPA) prescription is on the steep decline these days because of adverse impacts on estrogen in CHD [14] and breast cancer [15]. Thus, the search for a safe and effective progestogen for MHT is one of the top-priority matters in the field of menopause. The effects of progestogen on BP have been less well studied to date. Our group [16] previously reported that micronized progesterone (MP4), combined with CEE, exerted favorable impacts on ambulatory BP in a prospective study.

The purpose of this study was to evaluate the impact of MP4 added to PEG on ambulatory BP and arterial stiffness in postmenopausal Korean women with grade 1 hypertension.

Methods
Study participants
A total of 61 postmenopausal women aged 57.3 ± 4.9 years (range: 49–75 years) with grade 1 hypertension were enrolled in this study. Women were considered postmenopausal if their duration of amenorrhea was at least 12 months or a serum follicle-stimulating hormone (FSH) value of 30 mIU/mL or higher was recorded. According to clinic BP measured at the arm, grade 1 hypertension was defined as an SBP of 140 to 159 mmHg or a
DBP of 90 to 99 mmHg. Women with uncontrolled hypertension using antihypertensive medication for at least six months were also enrolled and asked to maintain their current BP medication. In addition, women whose BP was controlled but who wanted to hold their BP medication were included if the BP rebounded only to grade 1 after two weeks of washout. Patients with symptomatic coronary heart disease or stroke were not eligible. Women were also excluded if they had current or recent (within one year prior to enrollment) smoking; uncontrolled diabetes mellitus (glycated hemoglobin > 8%); secondary hypertension; hypertension with serious target organ injury suspected; current or recent (within three months before the time of the study entry) MHT use; or contraindications for MHT including acutely impaired liver function, breast cancer, and venous thrombosis. Informed consent was obtained from the participant and the current study was approved by the Institutional Review Board of the hospital (IRB No: 2010-12-019-001).

Study design
We conducted a prospective, randomized, double-blind, placebo-controlled trial that spanned 12 weeks from November 2011 to January 2017. Participants were randomly allocated in a 1:1 ratio to placebo (n = 16), estrogen therapy (ET) (n = 19), or estrogen + progestogen therapy (EPT) (n = 17). The allocation of treatment was based on randomization codes created by the SAS program (SAS Institute, Cary, NC, USA). No other specific randomization stratification factor was applied. PEG (0.1%, 1 g./d; Samil Pharm. Co., Seoul, Korea) was applied to the forearm before sleep. For EPT, oral MP4 (0.1%, 1 g./d; Besins Healthcare, Brussel, Belgium) was added to PEG. Two kinds of placebo identical in appearance to the active treatment drug were kindly supplied by each drug company.

Clinic BPs were followed up with at four and 12 weeks. Participants whose BP increased during the study to grade 2 or higher were removed from the study population and closely followed up with by an internist. The primary and secondary endpoints of the current study were ambulatory BPs and arterial stiffness, respectively.

Outcome measures
ABPM was performed for a 24-hour period at baseline and 12 weeks after MHT using an automated portable device (Suntech Medical Instruments Inc., Raleigh, NC, USA), which used the oscillometric method and R-wave gating to measure BP, as previously described [16]. Briefly, the mean SBP and DBP values for the daytime (07.00–22.00) and nighttime (22.00–07.00) periods were calculated as the mean values of the hourly averages.

The nightly dip in BP was determined as the difference between the daytime and nighttime BPs. The BP load was calculated as the percentage of BP that was higher than predefined values (135/85 for the daytime period and 130/80 for the nighttime period).

Arterial stiffness was evaluated with both pulse-wave velocity (PWV) using the incident wave and augmentation index (AIx) using the reflected wave. Brachial–ankle PWV (baPWV) (VP-1000; Colin, Komaki, Japan) measurements were made after at least five minutes of rest. The volume-rendering method was used in PWV determination. The right- and left-side baPWVs were measured and the average of the bilateral baPWV values was adopted into the analysis. Blood pressures were obtained from all four limbs simultaneously using the oscillometric method. The ankle–brachial index (ABI) was calculated. The validity and reproducibility of this method have been previously reported [17]. The peripheral pulse pressure curve was recorded at the radial artery by means of applanation tonometry (SphygmoCor; Atcor Medical, Sydney, Australia). The SphygmoCor personal computer software calculates aortic SBP and aortic pulse pressure (PP) (i.e., the difference between SBP and DBP) by the transformation of the radial pulse wave. The inflection point was identified within the time domain, indicating the arrival of the reflected wave in the ascending aorta. The BP at this point in time is the inflection pressure, while the difference between aortic SBP and inflection pressure is augmentation pressure (AP). The AIx was then calculated by AP/aortic PP × 100 [18].

Hormone assay
Blood concentrations of FSH, estradiol, and progesterone were measured at baseline and 12 weeks of treatment, using radioimmunoassay (DIA source, Belgium for FSH; Beckman Coulter, Czech for estradiol and progesterone).

Statistical analysis
Statistical analyses were performed using SAS version 9.4. Data are expressed as means ± standard deviations or numbers (%). Baseline characteristics between the three study groups were compared using the Kruskal–Wallis test for continuous variables or Fisher’s exact test for categorical variables. Between-group comparisons of the outcome measures were examined with the Kruskal–Wallis test for three groups or the Wilcoxon rank-sum test for two groups and within-group comparisons were examined with the signed-rank test. The difference of 12-week values among the three groups was analyzed with adjustment for baseline values using linear regression analysis. For all analyses, a two-tailed P-value < 0.05 was considered to be statistically significant.
Results
The flow diagram for the study is displayed in Fig. 1. Sixty-one women took part in this trial and three women decided to withdraw before treatment in each group. As a result, a total of 52 received the study drug, including 16 placebo cases, 19 ET cases, and 17 EPT cases. Overall, only one woman in the ET group dropped out due to being lost to follow-up, so 51 participants were finally analyzed.

Baseline characteristics of the study participants are summarized in Table 1. All variables except a medical history of dyslipidemia were comparable among the three groups. Table 2 shows blood hormone concentrations: there was no difference in FSH, estradiol, and progesterone at baseline between the three groups, but significant group difference was found at 12 weeks in all three hormones.

No participant discontinued the study because of a BP increase to grade 2 hypertension or higher. The effects of MHT on ambulatory BPs are summarized in Table 3. There was no difference in BP measurements between the three groups. Changes from baseline were also comparable between the three groups. The changes from baseline in 24-hour SBP in the placebo, ET, and EPT groups were $-1.5 \pm 11.7$, $-1.0 \pm 13.4$, and $-1.5 \pm 9.3$ mmHg, respectively ($P = 0.85$); those in 24-hour DBP were $-2.5 \pm 7.9$, $-0.3 \pm 6.1$, and $-1.3 \pm 5.4$ mmHg, respectively ($P = 0.38$). Relative to baseline, the daytime heart rate (HR) was significantly decreased in the EPT group (change from baseline; $-2.5 \pm 5.7$ bpm, $P = 0.03$). The pooled results of the ET and EPT groups did not suggest a difference in any ambulatory BP as compared with either the placebo group or baseline (see Additional file 1).

There was no participant with a baseline ABI measurement of 0.9 or less, which is highly suggestive of peripheral arterial disease. As shown in Table 4, the main markers of arterial stiffness did not differ between the three groups. Within the EPT group, PWV significantly fell after 12 weeks as compared with baseline (change from baseline; $-0.6 \pm 1.4$ m/s, $P = 0.04$). After controlling for baseline value, the linear regression analysis of PWV disclosed that the relationship between baseline and 12-week values was significantly different among the three groups ($P = 0.02$) (Fig. 2). The relationship was significantly different between the placebo and ET groups (beta value $= -0.61$, standard error $= 0.27$; $P = 0.03$) and between the placebo and EPT groups (beta value $= -0.74$, standard error $= 0.27$; $P = 0.01$) but was comparable between the ET and EPT groups, meaning that the ET and EPT groups showed a significantly greater decrease in PWV from baseline relative to the placebo group. As compared with baseline, the aortic DBP was significantly lowered after 12 weeks of ET ($P = 0.03$). Further, AIx, but not corrected AIx, was significantly diminished within the ET group ($P = 0.03$). When ET and EPT were combined, between-group comparisons showed that differences between at baseline and 12 weeks did not differ. However, within-group analysis revealed that the active treatments decreased the PWV ($P = 0.02$), AIx ($P = 0.02$), and corrected AIx at a HR of...
Table 1: Baseline characteristics of study participants

|                      | Placebo (n = 16) | ET (n = 18) | EPT (n = 17) |
|----------------------|------------------|------------|-------------|
| **Age (years)**      | 56.6 ± 3.8       | 57.7 ± 6.3 | 57.5 ± 4.4  |
| **Age at menarche (years)** | 14.8 ± 1.1   | 14.9 ± 2.4 | 15.1 ± 1.7  |
| **Type of menopause** |                  |            |             |
| Natural              | 15 (92.7)        | 16 (88.9)  | 16 (94.1)   |
| Surgical             | 1 (6.3)          | 2 (11.1)   | 1 (5.9)     |
| **Age at menopause (years)** | 52.2 ± 2.8     | 49.8 ± 4.8 | 51.2 ± 3.9  |
| **Duration from menopause (months)** | 39.6 ± 31.1   | 62.9 ± 41.4 | 63.9 ± 61.6 |
| **Parity**           | 1.9 ± 0.9        | 2.1 ± 0.4  | 2.2 ± 0.5   |
| **Body mass index (kg/m²)** | 23.5 ± 1.7      | 24.6 ± 2.9 | 24.9 ± 3.2  |
| **Medical history**  |                  |            |             |
| Diabetes mellitus    | 1 (6.25)         | 0 (0.0)    | 1 (5.9)     |
| Hyperlipidemia* [statin use] | 2 (12.5) [2]    | 8 (44.4) [3] | 2 (11.8) [2] |
| Antihypertensive medication use | 11 (68.8)     | 11 (61.1)  | 8 (47.1)    |
| **History of hormone use** |              |            |             |
| Oral contraceptive   | 2 (12.5)         | 1 (5.6)    | 0 (0.0)     |
| Menopausal hormone therapy | 4 (25.0)       | 7 (38.9)   | 5 (29.4)    |
| Current smoking      | 0 (0.0)          | 1 (5.6)    | 0 (0.0)     |
| Alcohol consumption  | 1 (6.3)          | 3 (16.7)   | 4 (23.5)    |
| Family history of hypertension | 7 (43.8)      | 13 (72.2)  | 8 (47.1)    |

Data are presented as means ± standard deviations or numbers (%)

ET estrogen therapy, EPT estrogen + progestogen therapy

*P-value for between-group differences < 0.05, by Fisher’s exact test

Table 2: Blood hormone levels in study participants with menopausal hormone therapy

|                      | Placebo (n = 16) | ET (n = 18) | EPT (n = 17) |
|----------------------|------------------|------------|-------------|
| **Baseline** 12 weeks |                  |            |             |
| **Change from baseline** |              |            |             |
| FSH*               | 54.6 ± 17.6      | 53.7 ± 17.2| -0.3 ± 16.9 |
| E2*                | 15.5 ± 16.8      | 42.0 ± 48.0| 23.2 ± 56.3 |
| P4*                | 0.2 ± 0.1        | 0.1 ± 0.1  | -0.1 ± 0.1  |

Data are presented as means ± standard deviations

ET estrogen therapy, EPT estrogen + progestogen therapy, FSH follicle stimulating hormone (mIU/mL), E2 estradiol (pg/ml), P4 progesterone (ng/ml)

*P-value for between-group difference at 12 weeks of treatment < 0.05, by the Kruskal Wallis test

P-value for within-group difference between baseline and 12 weeks of treatment < 0.05, by the signed-rank test

75bpm (P = 0.01) (Fig. 3A). In addition, the pooled results suggested significant reductions in aortic SBP (P = 0.02) and DBP (P = 0.00) relative to baseline (Fig. 3B)

The placebo group reported no adverse effect, whereas three participants (16.7%) in the ET group and seven (41.2%) in the EPT group experienced adverse effects including vaginal bleeding and breast change most frequently.

Discussion

The present study was carried out to examine the impacts of MP4 combined with PEG in postmenopausal Korean women with grade 1 hypertension. The main finding was that there was no difference in ambulatory BP between ET and EPT. Further, ET and EPT comparably decreased the PWV from baseline as compared with the placebo. MP4 might not adversely influence the estrogen effect on ambulatory BP and arterial stiffness.

As compared with CEE, adopting a transdermal route for estrogen showed a lower risk of venous thrombosis [19] and stroke [20]. MP4 is also considered safer than MPA in terms of CVD, venous thrombosis, and breast cancer [21]. Accordingly, PEG/MP4 may be a favorable regimen of MHT for postmenopausal women with hypertension.

The current study reported that the results of ABPM were comparable among the three groups overall. The estradiol patch was reported previously to decrease BP...
Table 3: Effect of menopausal hormone therapy on ambulatory blood pressure measures

|                      | Placebo (n = 16) | ET (n = 18) | EPT (n = 17) |
|----------------------|------------------|-------------|--------------|
|                      | Baseline         | 12 weeks    | Change from  |
| Baseline             |                  |             | baseline     |
|                      |                  |             | Baseline     |
|                      |                  |             | 12 weeks     |
|                      |                  |             | Change from  |
|                      |                  |             | baseline     |
| **Daytime measurement** |                 |             |             |
| SBP                  | 147.9 ± 14.3     | 146.9 ± 11.0| -0.9 ± 12.5  |
| DBP                  | 92.8 ± 9.4       | 91.0 ± 10.6 | -2.3 ± 8.7   |
| HR                   | 72.8 ± 6.8       | 72.0 ± 7.4  | 0.1 ± 6.4    |
| BP loada             | 77.0 ± 26.0      | 74.1 ± 25.5 | -2.4 ± 28.2  |
| SBP                  | 79.1 ± 25.9      | 77.8 ± 28.5 | -2.2 ± 32.1  |
| DBP                  | 59.9 ± 27.9      | 49.4 ± 32.6 | -10.8 ± 28.3 |
| **Nighttime measurement** |            |             |             |
| SBP                  | 139.9 ± 16.8     | 136.4 ± 12.6| -3.5 ± 12.4  |
| DBP                  | 85.3 ± 11.5      | 82.4 ± 9.4  | -3.2 ± 7.8   |
| HR                   | 64.0 ± 6.4       | 62.2 ± 6.6  | -1.2 ± 7.8   |
| BP loada             | 71.0 ± 25.9      | 69.7 ± 28.5 | -2.2 ± 31.7  |
| SBP                  | 79.1 ± 25.9      | 77.8 ± 28.5 | -2.2 ± 32.1  |
| DBP                  | 59.9 ± 27.9      | 49.4 ± 32.6 | -10.8 ± 28.3 |
| **24-hour measurement** |              |             |             |
| SBP                  | 146.0 ± 14.1     | 143.4 ± 10.5| -1.5 ± 11.7  |
| DBP                  | 91.0 ± 9.4       | 89.0 ± 9.9  | -2.5 ± 7.9   |

Data are presented as means ± standard deviations.

ET estrogen therapy, EPT estrogen + progestogen therapy, SBP systolic blood pressure (mmHg), DBP diastolic blood pressure (mmHg), HR heart rate (bpm), BP blood pressure

* proportion (%) of BP higher than the predefined cutoff level (135/85 mmHg for the daytime and 130/80 mmHg for the nighttime)

**BP difference (mmHg) between the daytime and nighttime

P-value for within-group difference between baseline and 12 weeks of treatment < 0.05, by the signed-rank test

Table 4: Effects of menopausal hormone therapy on arterial stiffness

|                      | Placebo (n = 16) | ET (n = 18) | EPT (n = 17) |
|----------------------|------------------|-------------|--------------|
|                      | Baseline         | 12 weeks    | Change from  |
| Baseline             |                  |             | baseline     |
|                      |                  |             | Baseline     |
|                      |                  |             | 12 weeks     |
|                      |                  |             | Change from  |
|                      |                  |             | baseline     |
| **PWV**              | 15.8 ± 2.2       | 16.3 ± 2.9  | 0.5 ± 1.5    |
| **Ao SBP**           | 137.3 ± 14.2     | 134.6 ± 13.7| -3.3 ± 13.8  |
| **Ao DBP**           | 85.2 ± 10.3      | 86.3 ± 9.9  | 0.4 ± 7.5    |
| **Ao PP**            | 52.1 ± 7.7       | 48.3 ± 7.4  | -3.7 ± 8.6   |
| **AIx**              | 0.40 ± 0.09      | 0.39 ± 0.09 | 0.0 ± 0.1    |
| **cAIx**             | 0.35 ± 0.07      | 0.34 ± 0.06 | 0.0 ± 0.1    |

Data are presented as means ± standard deviations.

ET estrogen therapy, EPT estrogen + progestogen therapy, Ao aortic, SBP systolic blood pressure (mmHg), DBP diastolic blood pressure (mmHg), PP pulse pressure (mmHg), PWV brachial–ankle pulse-wave velocity (m/s), AIx augmentation index, cAIx corrected augmentation index at heart rate 75 bpm

*P-value for within-group difference between baseline and 12 weeks of treatment < 0.05, by the signed-rank test
in hypertensive postmenopausal women [11]; the study authors found that a higher (100 µg/d) patch dose over the conventional (50 µg/d) dose significantly reduced both SBP and DBP during a 24-hour and daytime periods in postmenopausal women with untreated, mild to moderate hypertension. In the current study, however, neither SBP nor DBP were changed with ET. Previously, our group [16] found a significant negative correlation between baseline BP and BP change with MHT. The current study recruited women with grade 1 hypertension due to potential ethical issue and a lower dose of PEG (1 g./d) was given relative to the conventional dose (1.5 g./d) to explore the MP4 effects better. Additionally, the proportion of participants with untreated hypertension was lower. These differences might account, at least partly, for the negative result on ABPM.

Carotid–femoral PWV (cfPWV) is the gold standard for assessing aortic stiffness [22], which is measured by tonometry or Doppler and requires specialized training and exposure of the inguinal region. baPWV is a unique measure of systemic arterial stiffness applied using an oscillometric method, which is easy and reproducible and which is closely correlated with cfPWV [23]. This study showed that baPWV did not differ between the three groups initially. Compared with baseline, however, baPWV was declined with EPT. After controlling for the baseline value, regression analysis further revealed a statistically significant difference in the relationship between baseline and 12-week baPWV values among the three groups. Both the outcomes of the ET and EPT groups were similar to each other and different from the placebo, which suggests that MP4 does not alter the beneficial estrogen effect on baPWV. Arterial stiffness accelerates in the early postmenopausal phase and this might be related to estrogen deficiency [24], but the results of randomized controlled trials considering the estrogen effect on PWV differ by the presence of hypertension and route of administration. In normotensive women, estrogen therapy did not affect PWV regardless of the route of administration [25, 26]. In hypertensive women, an estrogen patch [27] but not oral estrogen [28] improved PWV independent of BP change, which agrees with the current study. Even though the mechanism is not fully understood, estrogen might improve arterial stiffness through vasodilation [16] and restoration of the aberrant vascular matrix [29]. Regarding progestogen, drospirenone, an antimineralocorticoid progestin, decreased PWV in normotensive women [30]. To our knowledge, this is the first study to report the effect of natural progesterone on arterial stiffness in women with hypertension. Further research is needed to clarify the underlying mechanism.

Aortic BPs and PP can be calculated by transformation of the radial pulse wave, and AIx is considered as a marker of aortic stiffness. Central BPs and AIx were not different between the three groups, but within-group analysis revealed decreases in the aortic DBP and AIx in the ET group. When combined, favorable impacts of active treatments on central aortic BPs and arterial stiffness became evident, likely due to enhanced statistical power. Despite a paucity of literature, MP4 might have independent action on BP, too. MP4 shows antimineralocorticoid effects and lowers the pressure response to angiotensin II. In addition, MP4 increases nitric oxide
production, suppresses vasoconstriction by the modulation of calcium channels, and decreases vascular resistance [16]. These findings at minimum exclude the adverse impact of MP4 on estrogen action. The aortic PP did not change probably because of the decreases in both SBP and DBP.

Of note, the current study reports that combined results of ET and EPT showed a decrease in central BPs.
but not peripheral BPs in postmenopausal women with grade 1 hypertension. The aortic SBP is actually lower than the brachial measurement, although this difference is highly variable between individuals. Furthermore, some studies suggested that central pressure is better related to future cardiovascular events as compared with brachial BP [31]. Likewise, a differential impact of BP-lowering drugs on central versus peripheral pressures was reported and aortic SBP and PP may be determinants of clinical outcomes [32]. This study also suggested that MHT might prevent an increase in central PP, probably by improving aortic stiffness. In addition, an increase in central BP may predate that in peripheral BP during the early phase of hypertension development [33]. Therefore, longer-term treatment might yield a reduction in peripheral BP later on.

In this study, the proportion of women with untreated hypertension was too low to study the MHT effect fully. Moreover, the sample size was small and the follow-up period was short. Additional large-scale, long-term trials are required to confirm our findings. We studied the effects of PEG and MP4 in postmenopausal women with grade 1 hypertension and the results of this study cannot be generalized to a higher degree of hypertension or other regimens of MHT.

Our study has several strengths worth mentioning. This was a randomized, double-blinded trial performed with separate arms for estrogen alone and the combination of estrogen and progestogen, respectively. Up-to-date technologies were applied to evaluate the MHT effect on hemodynamics. Impacts on central BP and PP as well as peripheral BP during a 24-hour period were assessed. In addition, both central and systemic arterial stiffness were examined. Nonetheless, the conclusions of this study are preliminary due to the limitations mentioned above. Further studies are warranted.

**Conclusions**

Our study suggests that MP4 does not negate estrogen effects on ambulatory BP and arterial stiffness in postmenopausal Korean women with grade 1 hypertension.

### Abbreviations

ABI: Ankle–brachial index; ABPM: Ambulatory blood pressure monitoring; AIC: Augmentation index; AP: Augmentation pressure; baPWV: brachial–ankle pulse-wave velocity; BP: Blood pressure; CEE: Conjugated equine estrogen; cPPWV: carotid–femoral PWV; CHD: Coronary heart disease; CVD: Cardiovascular disease; DBP: Diastolic blood pressure; ET: Estrogen therapy; EPT: Estrogen + progestogen therapy; FSH: Follicle-stimulating hormone; HR: Heart rate; MHT: Menopausal hormone therapy; MPA: Medroxyprogesterone acetate; MP4: Micronized progesterone; PEG: Percutaneous estradiol gel; PP: Pulse pressure; PWV: Pulse-wave velocity; SBP: Systolic blood pressure

### Supplementary information

The online version contains supplementary material available at https://doi.org/10.1186/s40885-021-00175-1.

### Additional file 1.

#### Acknowledgements

Not applicable.

#### Authors’ contributions

B-KY contributed to conceptualization, study design, data collection, data analysis, and data interpretation and drafted the article. J-S was responsible for study design, data collection, data analysis, data interpretation, and manuscript preparation. Y-MS was responsible for data collection, data analysis, data interpretation, and manuscript preparation. S-MK and K-AS were responsible for data collection and data management. JHY and S-JP were responsible for data collection, data interpretation, and manuscript preparation. All authors read and approved the final manuscript.

#### Funding

This work has been supported, in part, by the Samsung Medical Center Research Fund (PH01095291 and PH01095801), and the IN-SUNG Foundation for Medical Research (C-AS-811-1). The funding body did not have any role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

#### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

#### Declarations

**Ethics approval and consent to participate**

This study was approved by the Institutional Review Board of the Samsung Medical Center and informed consent was obtained from the participant.

**Consent for publication**

Not applicable.

**Competing interest**

The authors declare that they have no competing interests.

**Author details**

1. Department of Obstetrics, Gynecology, and Women’s Health, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 2. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 3. Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

**Received:** 26 September 2020 **Accepted:** 15 June 2021 **Published online:** 15 September 2021

#### References

1. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abyu G, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017;70:1–25.
2. Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75:285–92.
3. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104.
4. Yang WY, Melgarejo JD, Thys L, Zhang ZY, Boggia J, Wei FF, et al. Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. JAMA. 2019;322:409–20.
5. Oh YS. Arterial stiffness and hypertension. Clin Hypertens. 2018;24:17.
6. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–492.
